Trials / Terminated
TerminatedNCT00073008
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer With Either Bronchioloalveolar Carcinoma or No Smoking History
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW572016 (lapatinib) | tyrosine kinase inhibitor |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2003-11-17
- Last updated
- 2017-02-28
- Results posted
- 2010-01-06
Locations
31 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00073008. Inclusion in this directory is not an endorsement.